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Abstract 
Background:  Vitamin D is an important micronutrient possessing valuable and diverse biological effects 
that are related to periodontal disease pathogenesis. Vitamin D levels are regulated by fibroblast growth 
factor 23 (FGF23) which is strongly associated with inflammation. The aim of the present study was to 
explore the relation of vitamin D and FGF23 with periodontal disease through the assessment of their levels 
in gingival crevicular fluid (GCF) and serum in periodontitis patients before and after non-surgical 
periodontal therapy and to compare those levels with healthy controls in order to identify any possible 
correlation between them. Methods: Serum and GCF samples were collected at baseline and 3 months 
after therapy to evaluate levels of vitamin D3 and FGF23 using enzyme-linked immunosorbent assay 
(ELISA) in both study groups. Group I consisted of 15 controls who were systematically and periodontally 
healthy, while group II consisted of 15 subjects who were systematically healthy with stage II periodontitis. 
Results: A significant elevation in vitamin D3 levels in both GCF and serum were recorded 3 months after 
therapy with a 25.98% and 39.29% increase respectively. On the contrary, a significant reduction in mean 
values of FGF23 in both GCF and serum were found after treatment with a 49.75% and 39.28% decrease 
respectively. Conclusion: The results of the present investigation have shed light on a vital association of 
both FGF23 and vitamin D3 with periodontitis, where FGF23 is associated with periodontal inflammation 
and vitamin D3 is associated with periodontal health. 
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Introduction 
The onset and progression of periodontal disease 
are influenced by the delicate equilibrium 
between microbial virulence factors and the 
proportional reaction of the host. In this regard, 
nutritional factors may be very noteworthy since 
they have been implicated in several chronic 
inflammatory conditions that are interrelated with 
periodontitis, including type 2 diabetes, 
inflammatory bowel disease, rheumatoid arthritis, 
and cardiovascular diseases. Micronutrients 
including vitamins, amino acids, trace elements, 
and minerals are required only in small quantities 
by living organisms and are indispensable for 
human development and well-being.1 Among 
these important micronutrients, vitamin D occupies 
a distinguished place with its valuable and 
diverse biological effects. 
Vitamin D is a secosteroid prohormone 
that can be manufactured by skin cells exposed 
to ultraviolet (UV) radiation or ingested through 
normal dietary consumption. Vitamin D occurs in 
two forms namely D2 (ergocalciferol) and D3 
(cholecalciferol).2 Vitamin D3 is further 
hydroxylated in the liver into 25-hydroxyvitamin 
D3 (25(OH)D3), which is the most steady form of 
vitamin D in blood.3 Besides the well-known role 
of sustaining the equilibrium of calcium and 
phosphorus levels in blood, it also has an 
endorsing effect on bone remodeling.3,4 Low 
vitamin D levels are associated with a negative 
calcium balance, disturbed bone mineralization, 
and bone loss.5 Vitamin D3 is also vital to the 
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immune system as it augments the innate immune 
response by activating hydrogen peroxide 
secretion in monocytes, and stimulating 
neutrophils, monocytes, macrophages, and 
dendritic cells to synthesize antimicrobial 
peptides, as defensin and cathelicidin LL-37, 
which has an important role in promoting 
chemotaxis, the release of chemokines and 
cytokines, neutralization of bacterial endotoxins, 
wound healing, and increasing vascular 
permeability.1,6  
Vitamin D3 influences the specific immune 
response as well by affecting both humoral and 
cellular immunity which specifically extinguish 
various pathogens that are presented to them via 
macrophages and dendritic cells. As much as such 
immune processes protect the host against 
infections, they also harm periodontal tissue and 
might worsen the periodontal condition. Vitamin D 
suppresses T lymphocyte proliferation and B 
lymphocyte transformation into plasma cells and 
inhibits their antibody production, thus 
suppressing the overall unwanted effects. 
Moreover, vitamin D prevents the excessive 
specific immune response through the inhibition of 
cytokine release during bacterial invasion as 
interleukin (IL)-1, IL-6, IL-8, IL-12, and tumor 
necrosis factor (TNF) which are responsible for 
lymphocyte infiltration, deterioration of 
extracellular matrix, and bone resorption.5,7 
Therefore, vitamin D affects periodontal disease 
pathogenesis through immunomodulation, 
enhancing bone mineralization, decreasing bone 
resorption, and augmenting the fight against 
periodontal pathogens.8 The anti-inflammatory 
properties of vitamin D were also confirmed in 
previous studies where serum with higher vitamin 
D concentrations was found to contain less IL-6 
and leptin and more adiponectin, which inhibits 
nuclear factor-kappa B (NF-κB) and IL-6 
production, and induces anti-inflammatory 
cytokines IL-10 and IL-1 receptor antagonist (IL-
1Ra).9 
The fibroblast growth factors (FGF) family 
comprises 22 growth factors, with diverse 
functions in development and health, including the 
regulation of cell proliferation, differentiation, 
organogenesis, metabolism, and repair.10 
Fibroblast growth factors are divided into seven 
subgroups and are classified as paracrine, 
endocrine, and intracrine based on their action 
mechanisms.11 Fibroblast growth factor 23 is a 
recently discovered FGF which is produced under 
physiological circumstances by osteoblasts and 
osteocytes and functions as a circulating bone-
derived hormone that maintains phosphate 
homeostasis by binding to its receptor and klotho 
– its coreceptor in the parathyroid glands and 
kidney; therefore, it is designated as an 
endocrine FGF.10,12 The biologically active form 
of FGF23 is a 32 kDa glycoprotein with a half-
life of about 45-60 minutes in humans.13 
Osteocytes produce FGF23 in response to 
dietary intake of phosphate, and FGF23 will in 
turn increase phosphate excretion by the 
kidney.14,15  Additionally, FGF23 decreases 
circulating vitamin D levels by inhibiting 1-α-
hydroxylase in the kidney, which converts the 
prehormone 25-hydroxyvitamin D3 into the 
active hormone, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), and by augmenting 24-
hydroxylase production, which degrades 1,25-
dihydroxyvitamin D3 into the inactive form.13,15 
Fibroblast growth factor 23 also inhibits 
parathyroid hormone (PTH) secretion.16 
Consequently, FGF23 is considered a key 
regulator of vitamin D metabolism. 
Fibroblast growth factor 23 might also 
possess relevant physiological effects on bone 
mineralization by suppressing mRNA transcription 
of tissue-nonspecific alkaline phosphatase (TNAP) 
which regulates bone mineralization through 
cleaving the mineralization inhibitor 
pyrophosphate that osteoblasts secrete to avoid 
premature mineralization of osteoid.17,18 
Therefore, it can be presumed that production of 
FGF23 in osteocytes locally may not only 
contribute to compromised mineralization when 
excessively secreted in bone, but may also inhibit 
bone mineralization by down regulating TNAP 
expression.17,19 
Fibroblast growth factor 23 impairs the 
host defense against infections via inhibition of  
neutrophil recruitment which is the predominant 
leukocyte subset of the innate immune response.10 
Fibroblast growth factor 23 also stops β2-integrin 
activation on neutrophils, thus preventing the β2-
integrin interaction with intercellular adhesion 
molecule-1 (ICAM-1) on endothelial cells, leading 
to impeded neutrophil-endothelial cell adhesion 
and trans-endothelial migration of neutrophils; 
this could causatively link the elevation of FGF23 
serum levels with compromised host response in 
systemic inflammatory diseases.10,13 Fibroblast 
growth factor 23 also affects other leukocytes 
directly where it alters monocyte function via 1-
α-hydroxylase inhibition thus decreasing 1,25-
dihydroxyvitamin D3 synthesis which is suggestive 
of a greater influence of FGF23 on inflammation 
and immune response regulation.13,20 
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Bearing in mind the important influence of 
vitamin D on periodontal disease pathogenesis 
and the strong association of FGF23 with 
inflammation in addition to the regulating effect 
of FGF23 on vitamin D levels, we anticipated an 
association linking vitamin D3 and FGF23 to 
periodontitis. Therefore, to explore this hypothesis 
the present investigation was conducted to 
evaluate the effect of non-surgical periodontal 
therapy on the gingival crevicular fluid (GCF) and 
serum levels of vitamin D3 and FGF23 and on 
clinical parameters in periodontitis patients 
compared to healthy controls, and to recognize 
the correlation between them if present. 
Materials and Methods 
I. Sample Size Calculation 
Sample size was calculated based upon the 
results of Yuci et al. 2017 using GCF vitamin D 
level as the primary outcome.21 The effect size 
was 5.7, with alpha (α) level = 0.05 and beta (β) 
level = 0.20 (80% power); the minimum 
estimated sample size was 12 patients per group 
for a total of 24 patients. To compensate for a 
drop-out rate and the use of non-parametric tests, 
the sample size was increased to a minimum of 15 
patients per group for a total of 30 patients. 
Sample size calculation was performed using the 
computer software PS: Power and Sample Size 
Calculation version 3.1.2. 
II. Study Population 
The present controlled before-and-after study 
included a total of 30 subjects recruited from the 
Periodontology Clinic at the Faculty of Dentistry, 
Cairo University. The faculty Research Ethics 
Committee approved the study in line with the 
Helsinki Declaration of 1975. The study sample 
(n=30) was divided into 2 groups as follows: 
group I consisted of 15 controls who were 
systematically and periodontally healthy; group 
II consisted of 15 subjects who were 
systematically healthy with stage II periodontitis. 
Eligible patients were informed of the purpose of 
the study and the benefits of participation in the 
study and signed a written informed consent. 
III. Inclusion Criteria 
Individuals above 30 years of age, with a 
minimum of 20 natural teeth excluding third 
molars or teeth indicated for extraction were 
included in the present study. The periodontally 
healthy group had no or minimal clinical signs of 
inflammation as bleeding on probing sites ≤ 10% 
and probing depth (PD) of ≤ 3mm with no 
radiographic evidence of alveolar bone loss. 
Stage II periodontitis was diagnosed according to 
Papapanou et al. as having an interdental clinical 
attachment level (CAL) of 3-4 mm, 15-33% 
coronal radiographic bone loss that is mostly 
horizontal, no tooth loss due to periodontitis, and 
a maximum PD ≤ 5mm.22 
IV. Exclusion Criteria 
The following were deemed grounds for 
exclusion: pregnancy and lactation, smoking 
within the previous 5 years, non-surgical 
periodontal therapy within the preceding 6 
months or surgical periodontal therapy within the 
preceding 12 months, anti-inflammatory, 
antimicrobial, lipid-lowering (e.g. statins), and 
immunosuppressive therapy within the preceding 
6 months, or any systemic disease that can alter 
the course of periodontal disease (diabetes, 
hypertension, cardiovascular disease, metabolic 
syndrome, immune disease, malignant tumor, etc.). 
V. Outcomes of the Study 
The primary outcome of the study was GCF 
vitamin D3 level, while secondary outcomes 
included PD, CAL, gingival index (GI), plaque 
index (PI), serum level of vitD3, and GCF and 
serum levels of FGF23. These were measured at 
baseline and 3 months following periodontal 
therapy. 
VI. Periodontal Examination and Clinical 
Evaluation 
At baseline, patients eligible for the study were 
screened via a comprehensive periodontal 
examination and full periodontal charts were 
obtained. Periapical radiographs were taken at 
sites of attachment loss for diagnosis of the case. 
Probing depth, CAL, GI, and PI were recorded at 
baseline and 3 months after periodontal therapy. 
Probing depth was measured as the distance from 
the base of the pocket to the free gingival margin 
using a University of Michigan “O” probe with 
Williams markings. It was recorded at the 
following six points around the circumference of 
each tooth: mesio-buccal, mid-buccal, disto- 
buccal, disto-lingual, mid-lingual, and mesio-
lingual. Clinical attachment level was measured as 
the distance from the base of the pocket to the 
cemento- enamel junction at the same PD locations 
using the same periodontal probe. The degree of 
gingival inflammation was assessed by means of 
the GI. It was developed for assessment of the 
qualitative changes in the gingiva related to the 
areas of the tooth which make up the total 
circumference of the marginal gingiva. Plaque 
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Index was recorded to assess the patients’ 
compliance with oral hygiene practices that may 
affect the clinical outcome measures and clinical 
response to periodontal therapy.24 
VII. Gingival Crevicular Fluid Sample Collection 
Gingival crevicular fluid samples for subjects with 
a healthy periodontium were acquired from 
areas which showed no clinical inflammation (PI 
and GI = 0). For periodontitis patients, GCF 
samples were collected from the sites with the 
most obvious signs of clinical inflammation and the 
deepest PD with radiographic evidence of bone 
loss. Samples from the selected sites were 
collected as follows: all supragingival plaque was 
gently removed with sterile cotton rolls and the 
tooth was air dried gently and isolated with 
sterile cotton rolls to avoid contamination with 
saliva. Paper strips were then placed gently into 
the sulcus or pocket until minimal resistance was 
felt for 30 seconds.23 Any strip contaminated with 
blood or saliva was discarded. Samples were 
then placed into sterile Eppendorf containers, and 
stored immediately at −80°C until biochemical 
analysis. 
VIII. Vitamin D Detection 
Vitamin D3 was assessed in all patients and 
controls using a human 1,25-dihydroxyvitamin D3 
enzyme-linked immunosorbent assay (ELISA) kit,a 
which uses the double antibody sandwich 
technique to detect vitamin D3 in samples. 
Standards and test samples were added to a 96-
well plate which was pre-coated with human 
vitamin D3 antibody and they were subsequently 
incubated. Vitamin D3 antibodies labeled with 
biotin were then added and joined with 
streptavidin-horseradish peroxidase (HRP) to 
form immune complexes which were incubated 
and washed to eradicate the uncombined 
enzyme. Chromogen solutions A and B were then 
added, and the degree of color change of the 
liquid to yellow was observed. The human vitamin 
D3 captured on the plate was proportional to the 
density of the yellow color. 
IX. Fibroblast Growth Factor 23 Detection 
Fibroblast growth factor 23 was measured using 
a human FGF23 ELISA kit.b Using the double-
sandwich ELISA technique, the pre-coated human 
FGF23 monoclonal antibody was detected by a 
biotin labeled polyclonal antibody. The biotin 
labeled antibody and the samples were added 
 
a Shanghai Sunred Biological Technology Co., 
Ltd, Shanghai, China 
to the ELISA plate wells and were subsequently 
washed out with phosphate-buffered saline (PBS) 
or tris-buffered saline (TBS). Streptavidin-HRP 
conjugates were then added to the ELISA wells 
and 3,3′,5,5′-tetramethylbenzidine (TMB) 
substrate was used for coloring after the reactant 
was meticulously washed out with PBS or TBS. TMB 
reacted with streptavidin-HRP to produce a blue 
byproduct which was then converted to yellow 
under the action of the stop solution (0.16M 
sulfuric acid). The optical density was used to 
determine the amount of FGF23 in the samples. 
Values were expressed in relative units (RU)/ml, 
and 1 RU/ml roughly equates to 2 pg/ml 
according to the manufacturer. 
X. Periodontal Therapy 
Following proper examination and diagnosis, full 
mouth supragingival and subgingival scaling and 
root planing were performed on all patients over 
two weeks using scalers and Gracey curettes. All 
patients received oral hygiene instructions 
including tooth brushing using the modified bass 
technique and the use of interdental cleansing 
aids (dental floss and interdental brush) to be 
performed at least twice per day. No local or 
systemic antibiotics were prescribed for the 
patients. 
XI. Statistical Analysis 
All data were collected, tabulated, and subjected 
to statistical analysis. Statistical analysis was 
performed using the IBM SPSS Statistics software 
(version 16), while the Microsoft Excel software 
was used for data handling and graphical 
presentation. Measured variables were 
described using the mean, standard deviation 
(SD), range (minimum – maximum), standard error 
(SE), and 95% confidence interval of the mean. 
Shapiro-Wilk test of normality was used to test 
the normality hypothesis of all quantitative 
variables for appropriate selection of parametric 
and nonparametric tests. Almost all variables 
were found to be normally distributed and 
parametric tests were thus used. Several groups 
were compared using one-way analysis of 
variance (ANOVA) followed by Dunnett’s test for 
multiple comparisons with the control, while the 
paired sample t-test was used to compare 
pretreatment and posttreatment results for the 
same group. Results were correlated using the 
Pearson correlation coefficient. Significance level 
was set at P < 0.05 (S), while P < 0.01 was 
considered highly significant (HS).  Two-tailed 
b MyBioSource, Inc., San Diego, CA, USA 
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tests were assumed throughout the analysis for all 
statistical tests. 
Results 
A total of 30 subjects participated in the present 
study and were divided into two groups; group I 
consisted of 15 systemically healthy subjects with 
a healthy periodontium (5 males and 10 females) 
and a mean age of 45.4 years, while group II 
consisted of 15 subjects who were systematically 
healthy with stage II periodontitis (5 male and 10 
females) and a mean age of 46.73. Both gender 
and age range closely matched in the 
periodontitis and control groups. 
Regarding the clinical parameters at 
baseline and after 3 months, the Fisher’s exact 
test was applied for PI and GI and it revealed a 
statistically significant decrease in PI scores post-
operatively in periodontitis patients with a P 
value of 0.0002. A highly statistically significant 
decrease in GI scores post-operatively was also 
found with a P value of 0.0001. As regards to PD 
and CAL, results showed a highly statistically 
significant reduction (52.86%) in PD 
measurements from 4.67±0.49 at baseline to 
2.20±0.68 post-operatively (P < 0.001), and a 
highly statistically significant gain (53.57%) in 
CAL from 3.73±0.46 at baseline to 1.73±0.59 
post-operatively (P < 0.001).
Figure 1. Descriptive data of vitamin D3 and FGF23 mean values in both GCF and serum 
 
Descriptive data of vitamin D3 and 
FGF23 mean values in both GCF and serum are 
represented in Figure 1. The analysis of variance 
(ANOVA) test revealed a statistically significant 
difference between mean GCF vitamin D3, serum 
vitamin D3, GCF FGF23, and serum FGF23 at 
baseline and posttreatment in the periodontitis 
group and control group with P < 0.001. 
Dunnett’s test was used for multiple comparisons 
with the control and it revealed a statistically 
significant difference between the mean GCF 
vitamin D3, serum vitamin D3, GCF FGF23, and 
serum FGF23 levels in the control group 
compared to the pretreatment and posttreatment 
values of the periodontitis group (Table 1). In the 
periodontitis patients, vitamin D3 and FGF23 
levels at baseline were compared to their levels 
three months following nonsurgical periodontal 
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therapy using the paired sample t-test which 
revealed a highly statistically significant increase 
in vitamin D3 levels in both GCF and serum 
following treatment compared to baseline (P < 
0.001) with a 25.98% and 39.29% increase 
respectively (Table 2). As regards to FGF23 
levels, there was a highly statistically significant 
decrease in their mean values in both GCF and 
serum following treatment compared to baseline 
(P < 0.001) with a 49.75% and 39.28% 
decrease respectively. The mean % changes in 
vitamin D3 and FGF23 levels are represented by 
a bar chart in Figure 2.
 
Table 1. Multiple comparisons with the control using Dunnett’s test 
Dependent 
Variable 
  Mean 
Difference 
Standard 
Error 
P Value 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
GCF Vitamin D3 
(ng/ml) 
Pretreatment Control -1.73 0.11 0.00000** -1.99 -1.47 
Posttreatment Control -0.62 0.11 0.00000** -0.88 -0.36 
GCF FGF23 
(RU/ml) 
Pretreatment Control 34.27 1.81 0.00000** 30.12 38.41 
Posttreatment Control 7.53 1.81 0.00030** 3.39 11.68 
Serum Vitamin 
D3 (ng/ml) 
Pretreatment Control -12.76 1.38 0.00000** -15.92 -9.59 
Posttreatment Control -7.20 1.38 0.00001** -10.37 -4.04 
Serum FGF23 
(RU/ml) 
Pretreatment Control 24.65 1.60 0.00000** 20.99 28.30 
Posttreatment Control 3.89 1.60 0.03562* 0.23 7.54 
*Significant at P < 0.05; **highly significant at P < 0.001 
 
Table 2. Paired sample t-test used to compare pretreatment and posttreatment levels of vitamin D3 and       
FGF23 
    Paired Differences 
t df P Value      
95% 
Confidence 
Interval of 
Difference 
  Mean SD Mean SD Lower Upper 
GCF 
Vitamin D3 
(ng/ml) 
Pretreatment 4.26 0.30 
-1.11 0.28 -1.26 -0.95 -15.37 14 0.00000* 
Posttreatment 5.37 0.40 
GCF FGF23 
(RU/ml) 
Pretreatment 53.73 8.08 
26.73 8.39 22.09 31.38 12.34 14 0.00000* 
Posttreatment 27.00 2.33 
Serum 
Vitamin D3 
(ng/ml) 
Pretreatment 14.14 1.59 
-5.56 3.87 -7.70 -3.41 -5.56 14 0.00007* 
Posttreatment 19.69 3.77 
Serum 
FGF23 
(RU/ml) 
Pretreatment 52.85 6.34 
20.76 7.56 16.57 24.95 10.63 14 0.00000* 
Posttreatment 32.09 3.13 
*Highly significant at P < 0.001; df: degrees of freedom 
 A significant direct correlation was found 
between GCF and serum levels of FGF23, and a 
significant inverse correlation was found between 
serum levels of vitamin D3 and FGF23 (Table 3).   
Discussion 
The range of biological effects of vitamin D is not 
confined to maintaining the homeostasis of calcium 
and phosphate, but it also takes a crucial part in 
regulating cellular proliferation, tissue 
differentiation, and immune function. Vitamin D is 
also vital for a healthy periodontal status and this 
is supported by studies linking periodontitis to 
vitamin D receptor (VDR) gene polymorphisms.25 
The potential role of vitamin D3 in the prevention 
of periodontal disease was verified by Liu et al. 
who stated that gingival fibroblasts and 
periodontal ligament cells have the ability to 
convert 25-hydroxyvitamin D3 to 1,25-
dihydroxyvitamin through their 1-α-hydroxylase 
activity, thereby revealing an 
autocrine/paracrine function of vitamin D in the 
oral cavity.7 Vitamin D3 is the most stable form of 
the vitamin with a half-life of approximately 60 
days; therefore, its serum levels are regarded as 
a reliable indicator of the vitamin D status of an 
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individual.8 In the present study, in addition to 
assessing serum levels of vitamin D3, we also 
assessed GCF levels of the vitamin as they would 
reflect closely the local changes in the periodontal 
environment. 
The present investigation was conducted 
on a total of 30 subjects – of whom 15 were 
periodontitis patients and 15 were periodontally 
healthy controls – to evaluate the effect of non-
surgical periodontal treatment on clinical 
parameters and on the GCF and serum levels of 
both vitamin D3 and FGF23. Several previous 
studies investigated the role of vitamin D in 
periodontal health but to the best of our 
knowledge no previous study explored the 
relation with FGF23 and its possible link with 
periodontitis. 
Figure 2. Bar chart representing mean % changes in vitamin D3 and FGF23 levels 
The results of the present study revealed 
a statistically significant decrease in PI and GI 
scores post-operatively in periodontitis patients. 
Moreover, there was a 52.86% reduction in PD 
measurements and a 53.57% gain in CAL 3 
months post-operatively and both changes were 
highly statistically significant. This indicates a 
significant improvement of periodontal condition 
with a decrease in clinical signs of inflammation 3 
months following nonsurgical periodontal 
therapy. 
Regarding vitamin D3 levels, our results 
revealed that both GCF and serum levels of 
vitamin D3 were significantly lower in the 
periodontitis group compared to the healthy 
control group at baseline, and a significant 
increase was observed 3 months following 
nonsurgical periodontal therapy with a 25.98% 
and 39.29% increase in GCF and serum 
respectively. These results are in accordance with 
Dietrich et al. who reported that vitamin D3 levels 
were significantly and inversely correlated with 
attachment loss and that low serum levels of the 
vitamin were associated with signs of 
inflammation.26 In another study, it was reported 
that vitamin D3 may reduce susceptibility to 
gingival inflammation through its anti-
inflammatory effect.27 
Also in line with our results, a recent study 
that investigated the relationship between vitamin 
D3 level and chronic periodontitis showed an 
inverse relationship between serum level of 
vitamin D3 and periodontal disease.28 Likewise, 
another study reported that there was a positive 
relation between serum level of vitamin D3 and 
periodontal health in diabetic subjects. They also 
found that the elimination of periodontal infection 
would increase the serum level of vitamin D3.29 
Conflicting results were conveyed by Liu et al. 
who reported no difference in plasma vitamin D3 
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levels between controls and chronic periodontitis 
patients, whereas aggressive periodontitis 
patients demonstrated higher plasma vitamin D3 
levels than controls.30 Also in another study, it was 
found that GCF levels of vitamin D3 were 
elevated in periodontitis and rheumatoid arthritis 
patients compared to controls, while serum levels 
were not affected.21 
Table 3. Correlation between vitamin D3 and 
FGF23 levels in GCF and serum 
 
  r P Value 
GCF 
Vitamin 
D3 
GCF 
FGF23 
0.18 0.51156 
GCF 
Vitamin 
D3 
Serum 
Vitamin 
D3 
-0.04 0.87380 
GCF 
FGF23 
Serum 
FGF23 
0.55 0.03486* 
Serum 
Vitamin 
D3 
Serum 
FGF23 
-0.71 0.00322** 
*Significant at P < 0.05; **highly significant at P 
< 0.001 
 
As the present study is to our knowledge 
the first to address the relation of FGF23 to 
periodontal disease, there are no closely 
relatable data to compare our results with. 
However, FGF23 has been associated with other 
inflammatory diseases as chronic renal disease 
where inflammatory markers, as TNFα, IL-6, C-
reactive protein (CRP), and fibrinogen, have been 
reported to correlate positively with plasma 
FGF23 levels, which was associated with an 
increased severity of inflammation in such 
patients.31 These results agree with our findings of 
significantly elevated FGF23 levels in 
periodontitis patients that were also found to 
significantly decrease following periodontal 
therapy with resolution of clinical inflammation 
and a 49.75% and 39.28% reduction of FGF23 
levels in GCF and serum respectively. Our results 
were also in line with another study which stated 
that FGF23 levels were elevated in children with 
inflammatory bowel disease during flare-ups and 
decreased with remission.32 Moreover, the 
expression of FGF23 in the heart was found to be 
induced by chronic inflammation in cardiac 
fibroblasts, suggestive of a paracrine signaling 
mechanism where chronic inflammation induces 
cardiac FGF23.33 
The association of FGF23 to periodontitis 
that we anticipated is supported by its strong link 
to inflammation as it has been found to be 
expressed in proinflammatory macrophages and 
specifically upregulated by IFN-γ and 
lipopolysaccharides, which are readily available 
in the local periodontal environment especially 
during inflammation.34 Moreover, current 
research has established that FGF23 influences 
the host response to bacterial infections, possibly 
through inhibition of neutrophil activation and 
recruitment and altering monocyte function.13 It is 
possible that classic regulators of FGF23 as 
phosphate, calcium, vitamin D3, and PTH and 
novel factors related to pathologic circumstances, 
such as elevations of proinflammatory cytokines, 
regulate osteocyte and osteoblast production of 
FGF23 at variable levels and might contribute to 
FGF23 elevation during inflammation.35,36 A local 
increase in phosphate and calcium due to 
inflammation-induced excessive bone resorption 
might also stimulate FGF23 production in 
osteoblasts.37,38 This could explain the local 
elevation of FGF23 levels in the GCF of 
periodontitis patients encountered in our results 
which significantly and directly correlated with 
serum level of FGF23.  
While those mechanisms are important, 
inflammation also exerts a potent effect on 
FGF23 production through the regulation of iron 
metabolism, as chronic inflammation was reported 
to produce a state of “functional” iron deficiency 
due to sequestration of iron in the 
reticuloendothelial system leading to a decline in 
circulating iron despite sufficient total body iron 
stores which ultimately results in higher circulating 
levels of FGF23 .39 Therefore, inflammatory 
conditions contribute to elevated FGF23 levels 
and FGF23 also exhibits proinflammatory and 
immunomodulatory effects on macrophages and 
neutrophils, suggesting the existence of a “feed-
forward” loop whereby in inflammatory 
conditions, as periodontal disease, the effects of 
inflammation and FGF23 amplify each other, 
which might lead to adverse outcomes.10,34,39 
The inhibitory effect of FGF23 on vitamin 
D synthesis may result in reduced concentrations 
of circulating vitamin D3 in systemic inflammatory 
diseases in which FGF23 has been shown to be 
markedly boosted.40 This was in accordance with 
our results as the highest FGF23 levels were found 
in periodontitis patients and they were associated 
with the lowest vitamin D3 concentrations, and 
thus a significant inverse correlation between 
them was evident. This is also in agreement with 
Erben who reported that diseases characterized 
by excessive FGF23 blood levels are associated 
with low circulating vitamin D3 levels.19 Moreover, 
FGF23 can stimulate macrophages to express 
TNFα which plays a central role in soft and hard 
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tissue destruction in periodontitis.41 It was found 
that vitamin D3 can inhibit FGF23-induced TNFα 
expression from macrophages and that the 
proinflammatory effects of FGF23 can be counter 
regulated by vitamin D3.13,34 
Based on the counterregulatory effect of 
vitamin D3 on FGF23 proinflammatory function 
and the anti-inflammatory and 
immunomodulatory properties of vitamin D3, in 
addition to the endorsing effect of the vitamin on 
bone remodeling and promoting wound healing 
after periodontal surgery, we propose that 
sufficient intake of vitamin D either in diet or as a 
supplement would be beneficial in the 
prophylaxis of periodontal disease.8 The results 
of the present investigation have shed light on a 
vital association of FGF23 with periodontal 
disease and vitamin D3 with periodontal health, 
and we recommend that this association be further 
explored in future research. 
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